ArticleBreast cancer research and treatment2017
Association between survival time with metastatic breast cancer and aggressive end-of-life care.
Article in Breast cancer research and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Geographic and sociodemographic access to systemic anticancer therapies for secondary breast cancer: a systematic review.Systematic reviews · 2024Pooled it
- Randomized Trial of a Palliative Care Intervention to Improve End-of-Life Care Discussions in Patients With Metastatic Breast Cancer.Journal of the National Comprehensive Cancer Network : JNCCN · 2022Trial
- Palliative care use and end-of-life care quality in HR+/HER2- metastatic breast cancer.Breast cancer research and treatment · 2025Article
- Cancer Prognostic Awareness: Relations to Patient and Caregiver Quality of Life and Care Preferences.Journal of pain and symptom management · 2025Article
- Systemic anticancer therapy at the end of life: real-world insights from a tertiary oncology center in Israel.The oncologist · 2025Article
- Contemporary Patterns of End-of-Life Care Among Medicare Beneficiaries With Advanced Cancer.JAMA health forum · 2025Article
- Article
- Naming racism as a root cause of inequities in palliative care research: a scoping review.BMC palliative care · 2024Article
- Prevalence of aggressive care among patients with cancer near the end of life: a systematic review and meta-analysis.EClinicalMedicine · 2024Article
- Factors affecting the economic burden of breast cancer in southern Iran.BMC health services research · 2023Article
- Use of Anticancer Therapies and Economic Burden Near the End of Life in Japan: Results From Claims Database.JCO global oncology · 2022Article
- Primary care physician continuity, survival, and end-of-life care intensity.Health services research · 2022Article
- A prospective cohort study assessing aggressive interventions at the end-of-life among patients with solid metastatic cancer.BMC palliative care · 2022Article
- Healthcare Use during the Last Six Months of Life in Patients with Advanced Breast Cancer.Cancers · 2021Article
- Early-onset pancreatic cancer: an institutional series evaluating end-of-life care.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- End of life breast cancer care in women with severe mental illnesses.Scientific reports · 2021Observational
- High-Intensity End-of-Life Care Among Patients With GI Cancer in Puerto Rico: A Population-Based Study.JCO oncology practice · 2021Article
- Intensity of End-of-Life Care in a Cohort of Commercially Insured Women With Metastatic Breast Cancer in the United States.JCO oncology practice · 2021Article
- Chemotherapy use near the end-of-life in patients with metastatic breast cancer.Breast cancer research and treatment · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeFor women with stage IV breast cancer (BC), the association between survival time (ST) and use of aggressive end-of-life (EOL) care is unknown.
methodsWe used the SEER-Medicare database to identify women with stage IV BC diagnosed 2002-2011 who died by 12/31/2012. Aggressive EOL care was defined as receipt in the last month of life: >1 ED visit, >1 hospitalization, ICU admission, life-extending procedures, hospice admission within 3 days of death, IV chemotherapy within 14 days of death, and/or ≥10 unique physician encounters in the last 6 months of life. Receipt of aggressive EOL care and hospice in the last month of life were determined using claims, and multivariable analysis was used to identify factors associated with receipt. Costs of care were also evaluated.
resultsWe identified 4521 eligible patients. Of these, 2748 (60.8%) received aggressive EOL care. Factors associated with aggressive EOL care were race (OR 1.45, 95% CI 1.19-1.81 for blacks compared to whites) and more frequent oncology office visits (OR 1.56, 95% CI 1.28-1.90). Patients who lived >12 months after diagnosis were less likely to receive aggressive EOL care (OR 0.44, 95% CI 0.38-0.52), and more likely to utilize hospice (OR 1.43, 95% CI 1.21-1.69) compared to patients who lived ≤6 months. Patients with a shorter ST had significantly higher costs of care per-month-alive compared to patients with longer ST.
conclusionPatients with a shorter ST were more likely to receive aggressive EOL care and had higher costs of care compared to patients who lived longer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.